{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:47:11Z","timestamp":1791499631404,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,11,23]]},"DOI":"10.1038\/s41416-022-01992-3","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T01:02:25Z","timestamp":1664758945000},"page":"2043-2051","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients"],"prefix":"10.1038","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7418-9422","authenticated-orcid":false,"given":"Lourdes","family":"Mengual","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0415-0316","authenticated-orcid":false,"given":"Maria","family":"Frantzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Mokou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Ingelmo-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"Vlaming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel S.","family":"Merseburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C.","family":"Roesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Culig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Alcaraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3284-5713","authenticated-orcid":false,"given":"Antonia","family":"Vlahou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Mischak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine G.","family":"Van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"1992_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comperat EM, Dominguez, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81:75\u201394.","journal-title":"Eur Urol"},{"key":"1992_CR2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester RJ, Rodriguez O, Hernandez V, Turturica D, Bauerova L, Bruins HM, et al. European association of urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol. 2021;79:480\u20138.","journal-title":"Eur Urol"},{"key":"1992_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ctrv.2016.05.002","volume":"47","author":"WS Tan","year":"2016","unstructured":"Tan WS, Rodney S, Lamb B, Feneley M, Kelly J. Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treat Rev. 2016;47:22\u201331.","journal-title":"Cancer Treat Rev"},{"key":"1992_CR4","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstrom PU, Choi W, et al. Bladder cancer. Lancet. 2016;388:2796\u2013810.","journal-title":"Lancet"},{"key":"1992_CR5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk M, Burger M, Comperat EM, Gontero P, Mostafid AH, Palou J, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 update. Eur Urol. 2019;76:639\u201357.","journal-title":"Eur Urol"},{"key":"1992_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(09)60491-8","volume":"374","author":"DS Kaufman","year":"2009","unstructured":"Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239\u201349.","journal-title":"Lancet"},{"key":"1992_CR7","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00345-018-2505-2","volume":"37","author":"M Maas","year":"2019","unstructured":"Maas M, Bedke J, Stenzl A, Todenhofer T. Can urinary biomarkers replace cystoscopy? World J Urol. 2019;37:1741\u20139.","journal-title":"World J Urol"},{"key":"1992_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/bju.14574","volume":"124","author":"Y Freifeld","year":"2019","unstructured":"Freifeld Y, Lotan Y. Effect of blue-light cystoscopy on contemporary performance of urine cytology. BJU Int. 2019;124:251\u20137.","journal-title":"BJU Int"},{"key":"1992_CR9","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","volume":"71","author":"E Christensen","year":"2017","unstructured":"Christensen E, Birkenkamp-Demtroder K, Nordentoft I, Hoyer S, van der Keur K, van Kessel KEM, et al. Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer. Eur Urol. 2017;71:961\u20139.","journal-title":"Eur Urol"},{"key":"1992_CR10","first-page":"1104","volume":"9","author":"A Chakraborty","year":"2019","unstructured":"Chakraborty A, Dasari S, Long W, Mohan C. Urine protein biomarkers for the detection, surveillance, and treatment response prediction of bladder cancer. Am J Cancer Res. 2019;9:1104\u201317.","journal-title":"Am J Cancer Res"},{"key":"1992_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1470-2045(06)70584-8","volume":"7","author":"D Theodorescu","year":"2006","unstructured":"Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006;7:230\u201340.","journal-title":"Lancet Oncol"},{"key":"1992_CR12","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.1158\/1078-0432.CCR-09-0226","volume":"15","author":"E Schiffer","year":"2009","unstructured":"Schiffer E, Vlahou A, Petrolekas A, Stravodimos K, Tauber R, Geschwend JE, et al. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res. 2009;15:4935\u201343.","journal-title":"Clin Cancer Res"},{"key":"1992_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrurol.2015.100","volume":"12","author":"M Frantzi","year":"2015","unstructured":"Frantzi M, Latosinska A, Fluhe L, Hupe MC, Critselis E, Kramer MW, et al. Developing proteomic biomarkers for bladder cancer: towards clinical application. Nat Rev Urol. 2015;12:317\u201330.","journal-title":"Nat Rev Urol"},{"key":"1992_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/BLC-160073","volume":"3","author":"M Frantzi","year":"2017","unstructured":"Frantzi M, Vlahou A. Ten years of proteomics in bladder cancer: progress and future directions. Bladder Cancer. 2017;3:1\u201318.","journal-title":"Bladder Cancer"},{"key":"1992_CR15","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1158\/1078-0432.CCR-15-2715","volume":"22","author":"M Frantzi","year":"2016","unstructured":"Frantzi M, van Kessel KEM, Zwarthoff EC, Marquez M, Rava M, Malats N, et al. Development and validation of urine-based peptide biomarker panels for detecting bladder cancer in a multi-center study. Clin Cancer Res. 2016;22:4077\u201386.","journal-title":"Clin Cancer Res"},{"key":"1992_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44129-y","volume":"9","author":"M Krochmal","year":"2019","unstructured":"Krochmal M, van Kessel KEM, Zwarthoff EC, Belczacka I, Pejchinovski M, Vlahou A, et al. Urinary peptide panel for prognostic assessment of bladder cancer relapse. Sci Rep. 2019;9:7635.","journal-title":"Sci Rep."},{"key":"1992_CR17","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/ncponc0252","volume":"2","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pr Urol. 2005;2:416\u201322.","journal-title":"Nat Clin Pr Urol"},{"key":"1992_CR18","doi-asserted-by":"publisher","first-page":"46ps42","DOI":"10.1126\/scitranslmed.3001249","volume":"2","author":"H Mischak","year":"2010","unstructured":"Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med. 2010;2:46ps42.","journal-title":"Sci Transl Med"},{"key":"1992_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016;70:106\u201319.","journal-title":"Eur Urol"},{"key":"1992_CR20","doi-asserted-by":"crossref","unstructured":"Brierley JD, Brierley JD, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours, 8th ed. Chicester: John Wiley & Sons, Incorporated; 2016.","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"key":"1992_CR21","doi-asserted-by":"publisher","first-page":"e62837","DOI":"10.1371\/journal.pone.0062837","volume":"8","author":"\u00c0 Argil\u00e9s","year":"2013","unstructured":"Argil\u00e9s \u00c0, Siwy J, Duranton F, Gayrard N, Dakna M, Lundin U, et al. CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS ONE. 2013;8:e62837.","journal-title":"PLoS ONE"},{"key":"1992_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/rcm.1294","volume":"18","author":"N Neuhoff","year":"2004","unstructured":"Neuhoff N, Kaiser T, Wittke S, Krebs R, Pitt A, Burchard A, et al. Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption\/ionization and capillary electrophoresis\/mass spectrometry. Rapid Commun Mass Spectrom. 2004;18:149\u201356.","journal-title":"Rapid Commun Mass Spectrom"},{"key":"1992_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1021\/pr800401m","volume":"8","author":"J Jantos-Siwy","year":"2009","unstructured":"Jantos-Siwy J, Schiffer E, Brand K, Schumann G, Rossing K, Delles C, et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res. 2009;8:268\u201381.","journal-title":"J Proteome Res"},{"key":"1992_CR24","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/prca.200800024","volume":"2","author":"JJ Coon","year":"2008","unstructured":"Coon JJ, Zurbig P, Dakna M, Dominiczak AF, Decramer S, Fliser D, et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteom Clin Appl. 2008;2:964.","journal-title":"Proteom Clin Appl"},{"key":"1992_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/prca.201000155","volume":"5","author":"J Siwy","year":"2011","unstructured":"Siwy J, Mullen W, Golovko I, Franke J, Zurbig P. Human urinary peptide database for multiple disease biomarker discovery. Proteom Clin Appl. 2011;5:367\u201374.","journal-title":"Proteom Clin Appl"},{"key":"1992_CR26","doi-asserted-by":"publisher","unstructured":"DeLeo JM. Receiver operating characteristic laboratory (ROCLAB): software for developing decision strategies that account for uncertainty. In: 1993 (2nd) International Symposium on Uncertainty Modeling and Analysis. 1993; pp. 318\u201325. https:\/\/doi.org\/10.1109\/ISUMA.1993.366750.","DOI":"10.1109\/ISUMA.1993.366750"},{"key":"1992_CR27","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.eururo.2011.11.012","volume":"61","author":"MJ Roobol","year":"2012","unstructured":"Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol. 2012;61:577\u201383.","journal-title":"Eur Urol"},{"key":"1992_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.urolonc.2020.08.016","volume":"39","author":"K Ng","year":"2021","unstructured":"Ng K, Stenzl A, Sharma A, Vasdev N. Urinary biomarkers in bladder cancer: a review of the current landscape and future directions. Urol Oncol. 2021;39:41\u201351.","journal-title":"Urol Oncol"},{"key":"1992_CR29","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00345-018-2380-x","volume":"36","author":"F Soria","year":"2018","unstructured":"Soria F, Droller MJ, Lotan Y, Gontero P, D\u2019Andrea D, Gust KM, et al. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. World J Urol. 2018;36:1981\u201395.","journal-title":"World J Urol"},{"key":"1992_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/14789450.2018.1547193","volume":"16","author":"M Frantzi","year":"2019","unstructured":"Frantzi M, Latosinska A, Belczacka I, Mischak H. Urinary proteomic biomarkers in oncology: ready for implementation? Expert Rev Proteom. 2019;16:49\u201363.","journal-title":"Expert Rev Proteom"},{"key":"1992_CR31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.eururo.2019.04.035","volume":"76","author":"B Konety","year":"2019","unstructured":"Konety B, Shore N, Kader AK, Porten S, Daneshmand S, Lough T, et al. Evaluation of cxbladder and adjudication of atypical cytology and equivocal cystoscopy. Eur Urol. 2019;76:238\u201343.","journal-title":"Eur Urol"},{"key":"1992_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-018-0496-x","volume":"10","author":"AG van der Heijden","year":"2018","unstructured":"van der Heijden AG, Mengual L, Ingelmo-Torres M, Lozano JJ, van Rijt-van de Westerlo CCM, Baixauli M, et al. Urine cell-based DNA methylation classifier for monitoring bladder cancer. Clin Epigenet. 2018;10:71.","journal-title":"Clin Epigenet"},{"key":"1992_CR33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.juro.2007.03.034","volume":"178","author":"HB Grossman","year":"2007","unstructured":"Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol. 2007;178:62\u20137.","journal-title":"J Urol"},{"key":"1992_CR34","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.euo.2021.10.003","volume":"4","author":"E Laukhtina","year":"2021","unstructured":"Laukhtina E, Shim SR, Mori K, D\u2019Andrea D, Soria F, Rajwa P, et al. Diagnostic accuracy of novel urinary biomarker tests in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis. Eur Urol Oncol. 2021;4:927\u201342.","journal-title":"Eur Urol Oncol"},{"key":"1992_CR35","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/jnci\/djz173","volume":"112","author":"KR Yabroff","year":"2020","unstructured":"Yabroff KR, Zhao J, de Moor JS, Sineshaw HM, Freedman AN, Zheng Z, et al. Factors associated with oncologist discussions of the costs of genomic testing and related treatments. J Natl Cancer Inst. 2020;112:498\u2013506.","journal-title":"J Natl Cancer Inst"},{"key":"1992_CR36","doi-asserted-by":"publisher","first-page":"100883","DOI":"10.1016\/j.eclinm.2021.100883","volume":"36","author":"R Wendt","year":"2021","unstructured":"Wendt R, Thijs L, Kalbitz S, Mischak H, Siwy J, Raad J, et al. A urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients. EClinicalMedicine. 2021;36:100883.","journal-title":"EClinicalMedicine"},{"key":"1992_CR37","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-8587(20)30026-7","volume":"8","author":"N Tofte","year":"2020","unstructured":"Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 2020;8:301\u201312.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01992-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01992-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01992-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T02:04:26Z","timestamp":1677636266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01992-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,23]]}},"alternative-id":["1992"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01992-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.15.21267846","asserted-by":"object"}]},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]},"assertion":[{"value":"23 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prof. HM holds ownership interest in Mosaiques Diagnostics GmbH. Dr. MF and Dr. MM are employed by Mosaiques Diagnostics GmbH. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent forms were obtained and adhered to Institutional Review Board-approved guidelines. Ethical approval for this study was obtained by the Ethics Committee in Medical School of Hannover (ID:3274\u20132016). The study was performed in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}